Literature DB >> 20022709

Forkhead box M1 transcription factor: a novel target for cancer therapy.

Zhiwei Wang1, Aamir Ahmad, Yiwei Li, Sanjeev Banerjee, Dejuan Kong, Fazlul H Sarkar.   

Abstract

FoxM1 signaling has been reported to be associated with carcinogenesis. Therefore, the FoxM1 may represent a novel therapeutic target, and thus the development of agents that will target FoxM1 is likely to have significant therapeutic impact on human cancer. This review describes the mechanisms of signal transduction associated with FoxM1 and provides emerging evidence in support of its role in the carcinogenesis. Further, we summarize data on several FoxM1 inhibitors especially "chemopreventive agents" and these agents could be useful for targeted inactivation of FoxM1, which indeed could become a novel approach for the prevention and/or treatment of human cancer. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  FoxM1; cancer; cell signaling pathway; chemopreventive agents

Mesh:

Substances:

Year:  2009        PMID: 20022709      PMCID: PMC2838950          DOI: 10.1016/j.ctrv.2009.11.006

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  74 in total

Review 1.  FoxM1: at the crossroads of ageing and cancer.

Authors:  Jamila Laoukili; Marie Stahl; René H Medema
Journal:  Biochim Biophys Acta       Date:  2006-08-30

Review 2.  FOXM1, a typical proliferation-associated transcription factor.

Authors:  Inken Wierstra; Jürgen Alves
Journal:  Biol Chem       Date:  2007-12       Impact factor: 3.915

3.  Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression.

Authors:  Oona Delpuech; Beatrice Griffiths; Philip East; Abdelkader Essafi; Eric W-F Lam; Boudewijn Burgering; Julian Downward; Almut Schulze
Journal:  Mol Cell Biol       Date:  2007-04-23       Impact factor: 4.272

Review 4.  Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state.

Authors:  Kelly A Green; Jason S Carroll
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716

5.  Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes.

Authors:  Yongjun Tan; Pradip Raychaudhuri; Robert H Costa
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

Review 6.  Epidermal growth factor receptor mutations in lung cancer.

Authors:  Sreenath V Sharma; Daphne W Bell; Jeffrey Settleman; Daniel A Haber
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

7.  Cyclin E/Cdk2, P/CAF, and E1A regulate the transactivation of the c-myc promoter by FOXM1.

Authors:  Inken Wierstra; Jürgen Alves
Journal:  Biochem Biophys Res Commun       Date:  2008-01-17       Impact factor: 3.575

8.  Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells.

Authors:  Zhiwei Wang; Sanjeev Banerjee; Dejuan Kong; Yiwei Li; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

9.  FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors.

Authors:  Aamir Ahmad; Zhiwei Wang; Dejuan Kong; Shadan Ali; Yiwei Li; Sanjeev Banerjee; Raza Ali; Fazlul H Sarkar
Journal:  Breast Cancer Res Treat       Date:  2009-10-08       Impact factor: 4.872

10.  Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer.

Authors:  Nuran Bektas; Anette ten Haaf; Jürgen Veeck; Peter Johannes Wild; Juliane Lüscher-Firzlaff; Arndt Hartmann; Ruth Knüchel; Edgar Dahl
Journal:  BMC Cancer       Date:  2008-02-06       Impact factor: 4.430

View more
  74 in total

1.  FoxM1: a potential drug target for glioma.

Authors:  Yu Li; Sicong Zhang; Suyun Huang
Journal:  Future Oncol       Date:  2012-03       Impact factor: 3.404

2.  Lack of reelin modifies the gene expression in the small intestine of mice.

Authors:  P García-Miranda; M D Vázquez-Carretero; G Gutiérrez; M J Peral; A A Ilundáin
Journal:  J Physiol Biochem       Date:  2011-12-08       Impact factor: 4.158

3.  Inhibition of EZH2 and activation of ERRγ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway.

Authors:  Boyan Huang; Peiqiang Mu; Yan Yu; Wenya Zhu; Tianqing Jiang; Rong Deng; Gongkan Feng; Jikai Wen; Xiaofeng Zhu; Yiqun Deng
Journal:  Gastric Cancer       Date:  2020-06-11       Impact factor: 7.370

Review 4.  The two faces of FBW7 in cancer drug resistance.

Authors:  Zhiwei Wang; Hidefumi Fukushima; Daming Gao; Hiroyuki Inuzuka; Lixin Wan; Alan W Lau; Pengda Liu; Wenyi Wei
Journal:  Bioessays       Date:  2011-08-30       Impact factor: 4.345

5.  Effects of FOXM1 inhibition and ionizing radiation on melanoma cells.

Authors:  Vivienne S Lee; Lucinda S McRobb; Vaughan Moutrie; Estavam D Santos; Timothy L Siu
Journal:  Oncol Lett       Date:  2018-09-21       Impact factor: 2.967

6.  FoxM1 influences mouse hepatocellular carcinoma metastasis in vitro.

Authors:  Ningning Zhang; Yunpeng Xie; Benke Li; Zhen Ning; Aman Wang; Xiaonan Cui
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

7.  FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system.

Authors:  Chen Huang; Dacheng Xie; Jiujie Cui; Qi Li; Yong Gao; Keping Xie
Journal:  Clin Cancer Res       Date:  2014-01-22       Impact factor: 12.531

8.  MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.

Authors:  S S Gayle; R C Castellino; M C Buss; R Nahta
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

9.  MicroRNA-370 directly targets FOXM1 to inhibit cell growth and metastasis in osteosarcoma cells.

Authors:  Ning Duan; Xiaojing Hu; Xiaowei Yang; Huiguang Cheng; Wentao Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 10.  FOX(M1) news--it is cancer.

Authors:  Marianna Halasi; Andrei L Gartel
Journal:  Mol Cancer Ther       Date:  2013-02-26       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.